论文部分内容阅读
目的 探究熄风化湿方对腹泻型肠易激综合征患者的影响.方法 选取2013年6月-2016年6月该院收治的122例腹泻型肠易激综合征患者为研究对象,采用随机数表法分为对照组和观察组,各61例,分别给予马来酸曲美布汀和熄风化湿方治疗.对比临床疗效和治疗前后血清五羟色胺、肠黏膜细胞因子水平.结果 观察组和对照组患者的临床总有效率分别为95.07％(58/61)和73.76％(45/61),治疗后血清五羟色胺水平分别为(53.27±16.94)和(84.93±28.72)ng/ml,观察组患者治疗后肿瘤坏死因子α、白介素6及白介素10水平分别为(12.11±2.53)、(9.66±2.54)和(26.52±7.63)ng/L,对照组为(18.63±3.82)、(15.73±6.48)和(12.46±5.81)ng/L,两组比较差异有统计学意义(P＜0.05).结论 熄风化湿方治疗腹泻型肠易激综合征患者临床疗效佳,能改善肠动力紊乱,抑制肠道氧化应激反应.“,”Objective To investigate the effect of the prescription of Xifeng Huashi Decoction on diarrhea predominant irritable bowel syndrome.Methods A total of 122 patients of diarrhea type irritable bowel syndrome were selected as the research objects from June 2013 to June 2016 in our hospital,and randomly divided into control group and observation group,61 cases were in each group.The control group and the observation group were treated with Trinebutine Maleate and Xifeng Huashi Decoction respectively.The clinical efficacy and the levels of serum 5-HT and cytokines of intestinal mucosa were compared before and after treatment.Results In the observation group and the control group,the total clinical effective rates were 95.07％ (58/61) and 73.76％ (45/61) respectively,the serum 5-HT levels after treatment were (53.27 ± 16.94) and (84.93± 28.72) ng/ml respectively,the differences were significant between the two groups (P＜ 0.05).The post-treatment levels of TNF-alpha,IL-6 and IL-10 were (12.11 ±2.53),(9.66± 2.54) and (26.52 ± 7.63)ng/L respectively in the observation group,and (18.63± 3.82),(15.73± 6.48) and (12.46 ± 5.81)ng/L in the control group,the differences were significantly different (P ＜ 0.05).Conclusions Xifeng Huashi Decoction has good clinical curative effect in treatment of diarrhea type irritable bowel syndrome,can significantly improve the intestinal motility disorders,and inhibit intestinal oxidative stress reaction.